Novel Treatment Advances and Approaches
in the Prevention and Management of
Cytomegalovirus (CMV) Infection

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live webinar held on August 22, 2018.  If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from September 15, 2018 to September 30, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck & Co.

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT. Antiviral prophylaxis is effective against direct and indirect effects of CMV infection. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Novel antiviral therapies with different mechanisms of action have recently become available giving healthcare professionals new options in the management of this infection. This program will take a look at those advances and provide up to date strategies for the management of CMV infection.

Upon completion of this activity, participants will be able to:

  • Discuss the impact and burden of CMV infection in transplant recipients

  • Examine the efficacy and safety profiles of novel antivirals for the prevention and management of CMV in haematopoietic stem-cell transplant (HSCT) recipients

  • Identify patients who may benefit from antiviral treatment for CMV infection

  • Optimize clinical and economic strategies in the prevention of CMV in HSCT recipients

Faculty: Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Infection Control Section
Director of Clinical Virology
University of Texas MD Anderson Cancer Center


Dr. Chemaly serves as a consultant for Oxford Immunotec, Chimerix, Merck and Astellas. He has received grant/research support from: Chimerix, Merck, Novartis, Oxford Immunotec, and Shire.
In addition, Dr. Chemaly serves on the speaker's bureau for Merck.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue